Physician profile
David S Murphy
NPI 1467568675
$1,770.84
in general payments reported to CMS, 2019-2025
20 companies · $392 in 2025
The $392 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $269 · 2020: $124 · 2021: $346 · 2022: $359 · 2023: $200 · 2024: $80.88 · 2025: $392.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $673.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $673.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaukos Corporation | $412.55 | 2019-2025 | Idosetr, Istent Infinite |
| Allergan, INC. | $235.17 | 2020-2021 | |
| Abbvie INC. | $208.99 | 2022-2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $127.86 | 2019-2020 | |
| Rxsight INC | $125.66 | 2021-2025 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Contact Lens |
| Alcon Vision LLC | $82.12 | 2022-2023 | Hydrus Microstent, Eysuvis |
| Kala Pharmaceuticals, INC. | $80.87 | 2021-2022 | |
| Biotissue Holdings INC. | $72.71 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $56.59 | 2023 | |
| Bausch & Lomb Americas INC. | $53.51 | 2022-2024 | Xiidra, Miebo, Vyzulta |
| Oyster Point Pharma, INC. | $48.38 | 2022-2023 | Tyrvaya |
| Johnson & Johnson Vision Care, INC. | $47.61 | 2021 | |
| Vantage Technology LLC | $45.99 | 2025 | |
| Dompe US, INC. | $38.75 | 2021 | |
| Sight Sciences, INC. | $36.00 | 2025 | Omni Surgical System |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aerie Pharmaceuticals, INC. | $29.97 | 2019-2020 | |
| Ivantis, INC | $24.84 | 2021 | |
| Lilly USA, LLC | $15.81 | 2025 | Zepbound |
| Optos, INC. | $15.09 | 2019 | |
| Sun Pharmaceutical Industries INC. | $12.37 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.